The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy.